AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer
14 nov. 2023 10h00 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park...
Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
13 nov. 2023 07h05 HE
|
Celcuity Inc.
Received FDA clearance of IND to evaluate gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer (mCRPC) Entered into a...
North America Leads Chemotherapy at Home Services Market, Driven by Increasing Cancer Incidence and Provider Expansion
10 nov. 2023 07h58 HE
|
Research and Markets
Dublin, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The "Chemotherapy At Home Services Market Size, Share & Trends Analysis Report By Product (Oral, Infusion), By Cancer Type (Leukemia, Lung Cancer,...
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
07 nov. 2023 07h00 HE
|
Arvinas Inc.
– Enrollment continues in the 2L Phase 3 VERITAC-2 trial and study lead-in for the VERITAC-3 1L Phase 3 trial with vepdegestrant; Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – –...
Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call
06 nov. 2023 07h30 HE
|
Celcuity Inc.
MINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
ARTIDIS Launches Groundbreaking ANGEL Study With Over 2,700 Participants: Transforming Breast Cancer Diagnosis and Personalized Therapy Optimization at the Patient's Bedside
02 nov. 2023 08h00 HE
|
Artidis AG
Houston, Texas, and Basel, Switzerland, November 2nd, 2023 – As Breast Cancer Awareness Month concludes, ARTIDIS announces the launch of its global multicenter clinical trial, ARTIDIS Nanomechanical...
Arvinas to Participate in Upcoming Investor Conferences
02 nov. 2023 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences
01 nov. 2023 07h05 HE
|
Celcuity Inc.
MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
Andira Pharmaceuticals Achieves Remarkable Breast Cancer Tumor Regression with Lead Oncology Candidate XOXO4
25 oct. 2023 13h20 HE
|
US Capital Global
San Francisco, California, USA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- US Capital Global Securities LLC, an affiliate of US Capital Global, recently launched an investment opportunity of up to $5 million...
Make This Breast Cancer Awareness Month About More Than Awareness with Accarent Health
24 oct. 2023 14h38 HE
|
Accarent Health
Baltimore, MD, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Every October pink ribbons appear everywhere as the impact of breast cancer is brought to the forefront of national conversation. Awareness and...